论文部分内容阅读
本文报道一种新型国产单克隆抗体3A1与柔红霉素结合物(MAb3A1-DM)的Ⅰ期临床试验研究。共治疗13例T源性淋巴肿瘤患者,其中T-ALL 10例,T-NHL 3例。
This article reports the first phase of a new type of monoclonal antibody 3A1 and daunorubicin conjugate (MAb3A1-DM) phase Ⅰ clinical trials. A total of 13 patients with T-lymphoma were treated, including 10 T-ALL patients and 3 T-NHL patients.